Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.

Abstract

Dose intense CHOP protocols have been shown to improve outcome for people with non-Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Thirty-one client owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression-free interval (PFI) of 140 days [95% confidence interval (CI) 91-335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.

• Authors: J H Burton, E Garrett-Mayer, D H Thamm
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 11 Issue 4 Pg. 306-15 (Dec 2013) ISSN: 1476-5829 [Electronic] England
• PMID: 22548975 (Publication Type: Journal Article)
• Copyright: © 2012 Blackwell Publishing Ltd.

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Dog Diseases (drug therapy)
• Dogs
• Doxorubicin (therapeutic use)
• Drug Administration Schedule
• Lymphoma (drug therapy, pathology, veterinary)
• Prednisone (therapeutic use)
• Vincristine (therapeutic use)